HCAR2 Human Gene Knockout Kit (CRISPR)

CAT#: KN206527

HCAR2 - human gene knockout kit via CRISPR, HDR mediated




 HDR-mediated knockout kit validation

  See Other Versions

CNY 12,260.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
pCAS-Scramble, pCas-Guide vector with a scrambled sequence as a negative control (10 µg)
    • 10 ug

CNY 3,710.00


Rabbit Polyclonal Anti-HCAR2 Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00


HCAR2 (Myc-DDK-tagged)-Human G protein-coupled receptor 109A (GPR109A)
    • 10 ug

CNY 3,656.00
CNY 3,990.00

Specifications

Product Data
Format 2 gRNA vectors, 1 GFP-puro donor, 1 scramble control
Donor DNA GFP-puro
Symbol HCAR2
Locus ID 338442
Kit Components

KN206527G1, HCAR2 gRNA vector 1 in pCas-Guide CRISPR vector, Target Sequence: GTGGAAACAGAAAATCCACA

KN206527G2, HCAR2 gRNA vector 2 in pCas-Guide CRISPR vector, Target Sequence: CCGAGATGACTTCATTGTCA

KN206527-D, donor DNA containing left and right homologous arms and GFP-puro functional cassette.

pUC vector backbone in gray; Left arm sequence in blue; GFP-puro in green; Right arm in violet

CAACCAGTCT GTCCTCATCA AACAGGCAAC TACTGTCTTC TCAGCATTTC CAAAAGAAAT CATATGTCTG CTACTGTTTA TGTCATATGC CTGTTAATTT TTCATGCTAA TTCTTAGTGT TTCTGGAAAA CCTCACTGTT TGGCACCAAA AATTGTTATT GCTATTGTTG TTGTTTTGTT AATTATGTCA GCCAAGCAGA TGACGGTGAA TTAATTCTGC AACGTTGAGT ACTCAGTTGG CATACAAGCA CCCAGCCTTC CAAAGGGATG TCCTTCATGT TTCACTGATT TTCGAATGAC AGTCGGCTTG CCTAAACTTA TCCTTTACAT TTAAGACATT TTGTGGGTTC CCGTCTGCCC AGGGGATTCT TATTACTTGT TTATGCAAAC AGCAGGTTGC ATAAGAGCCT TGCTGGCTTT TTTTTTTTTT TTTTTTTTTA GAGATTTCGT AGTTTCCTGG TAACCATTCA GTCATCTATT TCAACACCCT GACATGACAT AAAGGCAGGC GTGGAACCAC ACGTTCACCA CACAGACACA CACCTCCTTG CTGGAGCATT CACTAGGCGA GGCGCTCCAT CGGACTCACT AGCCGCACTC AGCCGGATTT TCCTGTTCAA CCTGGCAGTG GCTGACTTTC TACTGATCAT CTGCCTGCCC TTCCTGATGG ACAACTATGT GAGGCGTTGG GACTGGAAGT TTGGGGACAT CCCTTGCCGG CTGATGCTCT TCATGTTGGC TATGAACCGC CAGGGCAGCA TCATCTTCCT CACGGTGGTG GCGGTAGACA GGTATTTCCG GGTGGTCCAT CCCCACCACG CCCTGAACAA GATCTCCAAT CGGACAGCAG CCATCATCTC TTGCCTTCTG TGGGGCATCA CTATTGGCCT GACAGTCCAC CTCCTGAAGA AGAAGATGCC GATCCAGAAT GGCGGTGCAA ATTTGTGCAG CAGCTTCAGC ATCTGCCATA CCTTCCAGTG GCACGAAGCC ATGTTCCTCC TGGAGTTCTT CCTGCCCCTG GGCATCATCC TGTTCTGCTC AGCCAGAATT ATCTGGAGCC TGCGGCAGAG ACAAATGGAC CGGCATGCCA AGATCAAGAG AGCCATCACC TTCATCATGG TGGTGGCCAT CGTCTTTGTC ATCTGCTTCC TTCCCAGCGT GGTTGTGCGG ATCCGCATCT TCTGGCTCCT GCACACTTCG

GE100003, scramble sequence in pCas-Guide vector

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
Reference Data
RefSeq NM_177551
Synonyms GPR109A; HCA2; HM74a; HM74b; NIACR1; Puma-g; PUMAG
Summary Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...